Biomea Fusion Announces Leadership Transition
Biomea Fusion (NASDAQ: BMEA), a clinical-stage diabetes and obesity medicines company, announced a significant leadership change with board member Mick Hitchcock, Ph.D. appointed as interim CEO, replacing Thomas Butler effective immediately.
Dr. Hitchcock, who has served on Biomea's board since March 2021, brings extensive pharmaceutical experience, including 27 years at Gilead Sciences in various vice president roles and 13 years at Bristol-Myers Squibb. His appointment comes at a important time following positive Phase II data for icovamenib in insulin-deficient patients.
The new interim CEO holds a Ph.D. in microbiology from the University of Melbourne and has significant experience in drug development and commercialization, particularly in antiviral treatments. He currently serves as Past Chair of the University of Nevada, Reno Foundation and as an Adjunct Professor of Microbiology at UNR Medical School.
Biomea Fusion (NASDAQ: BMEA), un'azienda in fase clinica che sviluppa farmaci per il diabete e l'obesità, ha annunciato un importante cambiamento nella leadership con la nomina del membro del consiglio Mick Hitchcock, Ph.D. come CEO ad interim, che sostituisce Thomas Butler con effetto immediato.
Il Dr. Hitchcock, che fa parte del consiglio di Biomea dal marzo 2021, porta con sé una vasta esperienza nel settore farmaceutico, inclusi 27 anni in vari ruoli di vicepresidente presso Gilead Sciences e 13 anni in Bristol-Myers Squibb. La sua nomina arriva in un momento cruciale, dopo i dati positivi della Fase II per l'icovamenib in pazienti con carenza di insulina.
Il nuovo CEO ad interim ha conseguito un dottorato in microbiologia presso l'Università di Melbourne e ha una significativa esperienza nello sviluppo e nella commercializzazione di farmaci, in particolare per i trattamenti antivirali. Attualmente ricopre il ruolo di Past Chair della Fondazione dell'Università del Nevada, Reno e di Professore Aggiunto di Microbiologia presso la Scuola di Medicina UNR.
Biomea Fusion (NASDAQ: BMEA), una empresa en etapa clínica dedicada a medicamentos para la diabetes y la obesidad, anunció un cambio significativo en su liderazgo con la designación de Mick Hitchcock, Ph.D. como CEO interino, reemplazando a Thomas Butler con efecto inmediato.
El Dr. Hitchcock, quien ha sido miembro de la junta de Biomea desde marzo de 2021, aporta una amplia experiencia farmacéutica, incluyendo 27 años en Gilead Sciences en varios roles de vicepresidente y 13 años en Bristol-Myers Squibb. Su nombramiento llega en un momento importante tras los datos positivos de la Fase II para icovamenib en pacientes con deficiencia de insulina.
El nuevo CEO interino posee un doctorado en microbiología de la Universidad de Melbourne y tiene una experiencia significativa en el desarrollo y comercialización de fármacos, particularmente en tratamientos antivirales. Actualmente, se desempeña como Past Chair de la Fundación de la Universidad de Nevada, Reno y como Profesor Adjunto de Microbiología en la Escuela de Medicina de UNR.
Biomea Fusion (NASDAQ: BMEA)는 당뇨병 및 비만 치료제를 개발하는 임상 단계의 회사로, 이사인 Mick Hitchcock, Ph.D.를 임시 CEO로 임명하며 Thomas Butler를 즉시 대체하는 중대한 리더십 변화를 발표했습니다.
Hitchcock 박사는 2021년 3월부터 Biomea의 이사로 활동해 왔으며, Gilead Sciences에서 27년간 여러 부사장 역할을 수행하고 Bristol-Myers Squibb에서 13년간 근무한 폭넓은 제약 경험을 가지고 있습니다. 그의 임명은 인슐린 결핍 환자에 대한 icovamenib의 긍정적인 2상 데이터 이후 중요한 시점에 이루어졌습니다.
새로운 임시 CEO는 멜버른 대학교에서 미생물학 박사 학위를 받았으며, 특히 항바이러스 치료제 개발 및 상용화에 대한 상당한 경험을 보유하고 있습니다. 현재 그는 네바다 대학교 리노 재단의 전 의장직과 UNR 의과대학의 미생물학 겸임 교수로 재직 중입니다.
Biomea Fusion (NASDAQ: BMEA), une entreprise en phase clinique spécialisée dans les médicaments pour le diabète et l'obésité, a annoncé un changement significatif dans sa direction avec la nomination de Mick Hitchcock, Ph.D. en tant que PDG par intérim, remplaçant Thomas Butler avec effet immédiat.
Le Dr Hitchcock, qui siège au conseil d'administration de Biomea depuis mars 2021, apporte une vaste expérience pharmaceutique, y compris 27 ans chez Gilead Sciences dans divers rôles de vice-président et 13 ans chez Bristol-Myers Squibb. Sa nomination intervient à un moment crucial suite à des données positives de la phase II pour l'icovamenib chez des patients déficients en insuline.
Le nouveau PDG par intérim détient un doctorat en microbiologie de l'Université de Melbourne et possède une expérience significative dans le développement et la commercialisation de médicaments, notamment dans les traitements antiviraux. Il est actuellement président sortant de la Fondation de l'Université du Nevada, Reno et professeur adjoint de microbiologie à la faculté de médecine de l'UNR.
Biomea Fusion (NASDAQ: BMEA), ein Unternehmen in der klinischen Phase, das Medikamente gegen Diabetes und Fettleibigkeit entwickelt, hat eine bedeutende Veränderung in der Unternehmensführung bekannt gegeben, indem Mick Hitchcock, Ph.D. als Interims-CEO ernannt wurde, der Thomas Butler mit sofortiger Wirkung ersetzt.
Dr. Hitchcock, der seit März 2021 im Vorstand von Biomea tätig ist, bringt umfassende Erfahrung in der Pharmaindustrie mit, einschließlich 27 Jahren bei Gilead Sciences in verschiedenen Vizepräsidentenrollen und 13 Jahren bei Bristol-Myers Squibb. Seine Ernennung erfolgt zu einem wichtigen Zeitpunkt nach positiven Phase-II-Daten für Icovamenib bei insulinmangelnden Patienten.
Der neue Interims-CEO hat einen Doktortitel in Mikrobiologie von der Universität Melbourne und verfügt über umfangreiche Erfahrung in der Arzneimittelentwicklung und -kommerzialisierung, insbesondere in der antiviralen Behandlung. Derzeit ist er als ehemaliger Vorsitzender der Stiftung der Universität Nevada, Reno und als außerordentlicher Professor für Mikrobiologie an der UNR Medical School tätig.
- Appointment of experienced pharmaceutical executive with 27 years at Gilead Sciences
- Recent positive Phase II clinical trial results for icovamenib in diabetes treatment
- Continuity maintained with existing board member taking interim CEO role
- Unexpected CEO departure could create temporary leadership uncertainty
- Interim nature of CEO appointment suggests potential ongoing leadership transition period
Board member Mick Hitchcock, named interim CEO replacing Thomas Butler.
COO and President Ramses Erdtmann continuing at Biomea in current role.
REDWOOD CITY, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Biomea Fusion, Inc. (“Biomea,” or the “Company”) (Nasdaq: BMEA), a clinical-stage diabetes and obesity medicines company, announced today an executive leadership change to help ensure the company realizes its full potential developing a novel therapy for diabetes. Specifically, Mick Hitchcock, a current board member since 2021, will succeed Thomas Butler as interim Chief Executive Officer. The change is effective immediately.
“As a long-time member of Biomea’s Board, I’ve had the privilege of closely supporting the company’s mission and strategic direction,” said Michael J.M. Hitchcock, Ph.D., Interim Chief Executive Officer and Board Member of Biomea Fusion. “I’m honored to step into this leadership role at such a promising moment in our development. The recent clinical progress with icovamenib, especially the positive Phase II data in insulin-deficient patients, marks a major milestone in our pursuit of a disease-modifying therapy for diabetes. I look forward to working even more closely with the exceptional Biomea team as we advance late-stage development efforts, prepare for regulatory engagement, and continue building a pipeline of innovative covalent therapies. Our mission remains clear: We aim to cure, and I’m committed to helping lead us there.”
Dr. Michael J. M. Hitchcock, Ph.D. (Mick) has served as a member of the Company’s board since March 2021. Dr. Hitchcock is currently a Past Chair of the University of Nevada, Reno (UNR) Foundation and Adjunct Professor of Microbiology at UNR Medical School, a position in which he has served since July 2016. Dr Hitchcock’s career in pharmaceutical research and development initially began with Bristol-Myers Squibb, where he served in several infectious disease research and project planning roles from 1980 through 1993. He joined Gilead Sciences, Inc. in 1993 and during his 27 years with the Company, he held a variety of positions, including vice president roles with responsibility for project and portfolio management, alliance management, strategic planning, medical affairs and specific areas of research. He also served as Senior Advisor at Gilead from 2009 through November 2019. During his career, he was involved in the development and commercialization of a number of anti-infective agents, primarily antivirals for treatment of HIV, HBV, influenza, CMV and other viral diseases. Dr. Hitchcock holds a Ph.D. in microbiology from the University of Melbourne, Australia and B.Sc. and M.Sc. degrees in biochemistry from the University of Manchester Institute of Science and Technology, England. He also conducted post-doctoral research at Georgetown University and NIH prior to joining industry.
Biomea continues to develop its product candidates for the treatment of diabetes based on its novel menin inhibition science.
“On behalf of the Board, we would like to thank Tom Butler for his important contributions to Biomea and his leadership to date,” said Dr. Hitchcock.
About Biomea Fusion
Biomea is a clinical-stage diabetes and obesity medicines company focused on the discovery and development of oral covalent small molecules to improve the lives of patients with diabetes, obesity, and metabolic disease. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein and offers a number of potential advantages over conventional non-covalent drugs, including greater target selectivity, lower drug exposure, and the ability to drive a deeper, more durable response.
We are utilizing our proprietary FUSION™ System to discover, design and develop a pipeline of next-generation covalent-binding small-molecule medicines designed to maximize clinical benefit for patients. We aim to have an outsized impact on the treatment of disease for the patients we serve. We aim to cure.
Visit us at biomeafusion.com and follow us on LinkedIn, X and Facebook.
Contact:
Meichiel Jennifer Weiss
Sr. Director, Investor Relations and Corporate Development
IR@biomeafusion.com
FAQ
What prompted Biomea Fusion's (BMEA) leadership change in March 2025?
What is Dr. Mick Hitchcock's background before joining BMEA as interim CEO?
What recent clinical milestone did BMEA achieve before the CEO transition?
Will BMEA's strategic direction change under the new interim CEO?
